Clinical Trial: Localized Leiomyosarcoma Biomarker Protocol

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: OBSERVATIONAL

Official Title: Pilot Study of ctDNA and Imaging Characteristics as Biomarkers of Disease-related Outcomes in Patients With Localized Leiomyosarcoma Receiving Chemotherapy

Brief Summary:

  • Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS).
  • Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following curative surgery.
  • Clinical trials of neoadjuvant or adjuvant anthracycline and ifosfamide have suggested that patients with localized STS who are at high-risk of metastasis may benefit from chemotherapy, but the magnitude of benefit in unselected patient population is relatively small.
  • Currently, patient age, and tumor size and grade are used to assess risk of metastases and survival
  • Studies evaluating tumor response by imaging and histopathology have not established correlation between tumor characteristics as biomarkers for risk of metastasis or sarcoma recurrence.
  • Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic LMS and may serve as biomarker of tumor response to chemotherapy.
    Blood samples will be collected prior to, during and after chemotherapy and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma.
    Tumor tissue will be collected and analyzed for changes in genes.
    Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis.
    Patients will be followed for 2 years after study entry for signs of sarcoma recurrence.
  • A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning.

Detailed Summary:
Sponsor: University of Michigan Rogel Cancer Center

Current Primary Outcome: Tumor characteristics from imaging will be compared to the presence of circulating tumor DNA , obtained from blood samples over multiple time points

Original Primary Outcome: Tumor characteristics from imaging will be compared to the presence of circulating tumor DNA , obtained from blood samples over multiple time points

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Michigan Rogel Cancer Center

Dates:
Date Received: June 08, 2021
Date Started: April 26, 2023
Date Completion: April 26, 2023
Last Updated: June 28, 2023
Last Verified: June 01, 2023